Magnesium as a Calcification Inhibitor.

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Vascular calcification (VC) significantly increases cardiovascular mortality in chronic kidney disease (CKD) patients.
• Low serum magnesium (Mg) levels are increasingly associated with VC and mortality in advanced CKD.
• Understanding Mg's role in VC is crucial for managing CKD complications.

Purpose of the Study:

• To review the current understanding of magnesium's impact on vascular calcification in CKD.
• To explore the molecular mechanisms by which Mg may protect against VC.
• To summarize evidence from clinical studies on Mg supplementation for VC in CKD.

Main Methods:

• Review of in vitro and preclinical in vivo studies on Mg and vascular calcification.
• Analysis of clinical data from pilot interventional studies on Mg supplementation.
• Synthesis of current literature on Mg's role in CKD-associated VC.

Main Results:

• In vitro and preclinical data suggest Mg protects vascular smooth muscle cells from calcification through various molecular pathways.
• Pilot clinical studies indicate that oral Mg supplementation can reduce VC in CKD patients.
• A clear association exists between low serum Mg and elevated VC and cardiovascular mortality in CKD.

Conclusions:

• Magnesium plays a protective role against vascular calcification in CKD.
• Oral Mg supplementation shows promise in reducing VC in CKD patients.
• Further research is warranted to fully elucidate Mg's therapeutic potential in CKD management.